Browse the full directors' dealings record of Inovalon Holdings, Inc., a listed equity based in United States. Shares trade on US US, under the authority of SEC (Form 4). Operating in the Healthcare & Pharma sector, Inovalon Holdings, Inc. has published 46 public disclosures. The latest transaction was filed on 29 November 2021 (Disposition). Among the most active insiders: Boldt Jonathan R. The full history is free.
0 of 0 declarations
Inovalon Holdings, Inc. (ticker: INOV) is a U.S.-based healthcare technology company listed on the NASDAQ in the United States. For French-speaking investors, Inovalon is best understood as a cloud-first healthcare data and analytics platform provider serving health plans, providers, specialty pharmacies and other participants across the healthcare value chain. Its core proposition is to help customers improve clinical quality, risk adjustment, compliance, revenue cycle performance and operational efficiency through proprietary data assets, software workflows and analytics delivered primarily through SaaS and DaaS models. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1619954/000161995421000042/inov-20201231.htm?utm_source=openai)) The company traces its origins to 1998 in Maryland, when it was founded as MedAssurant before evolving into Inovalon. That heritage matters: the business was built around healthcare data, measurement and population-scale analytics long before these themes became mainstream in digital health. Inovalon’s executive offices are located in Bowie, Maryland, at 4321 Collington Road, underscoring that its operating center remains firmly in the United States. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1619954/000161995421000042/0001619954-21-000042-index.html?utm_source=openai)) Inovalon’s main business lines are anchored in cloud-based platforms that connect data, analytics and workflow automation. The company sells solutions to payers, providers and pharmacies, with use cases spanning quality measurement, risk adjustment, claims management, revenue cycle management, pharmacy intelligence and broader population-health decision support. A key element of the investment case is the company’s ability to package these capabilities into scalable products rather than relying purely on services work. That platform orientation supports recurring revenue characteristics and makes Inovalon relevant to large enterprise healthcare customers. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1619954/000161995421000042/inov-20201231.htm?utm_source=openai)) From a competitive standpoint, Inovalon operates in a crowded but structurally attractive market that includes healthcare IT vendors, analytics specialists and data infrastructure providers. Its differentiation is based on the breadth of its data, the integration of its workflow tools, and its focus on highly regulated healthcare processes where accuracy, traceability and interoperability are critical. Management has also emphasized scale and customer breadth, with the business serving many leading U.S. health plans, providers and pharmacy organizations over time. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1619954/000161995421000042/inov-20201231.htm?utm_source=openai)) Recent developments are notable. Inovalon said it completed its multi-year transformation into a pure-play cloud-based SaaS and DaaS platform provider in early 2025, following the post-privatization restructuring of its business model. In 2025 and 2026, the company also announced or highlighted multiple AI-related and cloud partnerships, including collaborations involving AWS, Google Cloud, Oracle and Snowflake, reflecting a strategic push to expand automation, improve data accessibility and modernize healthcare operations. For investors, that means Inovalon is best viewed as a U.S. NASDAQ-listed healthcare software and data platform with a strong specialization in regulated workflows, a recurring-revenue profile, and continued optionality from AI-enabled product expansion. ([nasdaq.com](https://www.nasdaq.com/press-release/inovalon-launches-ai-solution-partnership-aws-help-health-plans-meet-new-radv-audit?utm_source=openai))